This discrepancy may indicate that while azacitidine can effectively downregulate BCL2 in the MDS-L line, the response in primary patient samples may be influenced by additional factors, such as the presence of BCL2L10. The gene discussed is BCL2; the disease is myelodysplastic syndrome.